The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy

Inclusion Criteria: * Adults aged 40-60 years diagnosed with diabetic polyneuropathy by a neurologist or neurology resident. * Patients with HbA1c levels between 7-10% within the past 30 days. * Willing to participate and able to sign the informed consent form. Exclusion Criteria: * Pregnant, breastfeeding, or planning pregnancy. * History of other neurological diseases such as stroke, myelopathy, alcoholic neuropathy, or compressive radiculopathy. * Significant renal impairment (creatinine \> 1.5× upper limit of normal), hepatic impairment (SGOT or SGPT \> 3× upper limit of normal), or severe cardiac disease (NYHA class III-IV heart failure). * History of alcohol consumption for ≥ 5 consecutive years. * Heavy smoker (Brinkman Index \> 600). * Known allergy or intolerance to DLBS1033. * Autoimmune disease, malignancy, or acute and/or chronic inflammatory conditions other than diabetic polyneuropathy. * Participation in another interventional pharmacological clinical study within 30 days prior to screening. * Currently taking anti-inflammatory and/or antioxidant medications.